By Ruixue Ran, Xiaoliang Chen and Justin Wang ( August 19, 2021, 5:29 PM EDT) -- The Standing Committee of the National People's Congress of China greenlighted a fourth amendment to the Patent Law of China on Oct. 17, 2020, which introduced a patent linkage system, comparable to the U.S. Hatch-Waxman Act, connecting marketing approval of small-molecule drugs to the resolution of potential patent infringement disputes relating to that drug.[1]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.